Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1088 Monotherapy and with Pembrolizumab in Advanced Solid Tumors
NCT05394350Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of MK-1088 in solid tumor (advanced stage) (6 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Experiencing a Dose-limiting Toxicity up to 21 days, Percentage of Participants Experiencing an Adverse Event and 1 more. Started Jul 2022; status: terminated.
02
Drugs
MK-1088
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05394350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394350.